Počet záznamů: 1

Unmasking Differential Effects of Rosiglitazone and Pioglitazone in the Combination Treatment with n-3 Fatty Acids in Mice Fed a High-Fat Diet

SYSNO ASEP	0367620
Druh ASEP	J - Článek v odborném periodiku
Zařazení RIV	J - Článek v odborném periodiku
Poddruh J	Článek ve WOS
Název	Unmasking Differential Effects of Rosiglitazone and Pioglitazone in the Combination Treatment with n-3 Fatty Acids in Mice Fed a High-Fat Diet
Tvůrce(i)	Kůs, Vladimír (FGU-C) Flachs, Pavel (FGU-C)_RID Kuda, Ondřej (FGU-C)_{RID, ORCID, SAI} Bardová, Kristina (FGU-C)_{RID, ORCID, SAI} Janovská, Petra (FGU-C)_{RID, ORCID} Svobodová, Michaela (FGU-C)_{RID, ORCID} Macek Jílková, Zuzana (FGU-C) Rossmeisl, Martin (FGU-C)_{RID, ORCID} Wang-Sattler, R. (DE) Yu, Z. (DE) Illig, T. (DE) Kopecký, Jan (FGU-C)_{RID, ORCID}
Zdroj.dok.	PLoS ONE. - : Public Library of Science - ISSN 1932-6203 Roč. 6, č. 11 (2011), e27126
Poč.str.	14 s.
Jazyk dok.	eng - angličtina
Země vyd.	US - Spojené státy americké
Klíč. slova	obesity ; TZD ; fish oil
Vědní obor RIV	FB - Endokrinologie, diabetologie, metabolizmus, výživa
CEP	NS10528 GA MZd - Ministerstvo zdravotnictví
CEZ	AV0Z50110509 - FGU-C (2005-2011)
UT WOS	000297197000028
DOI	10.1371/journal.pone.0027126
Anotace	We investigated whether pioglitazone (as well as rosiglitazone), a TZD-drug, could elicit the additive beneficial effects when combined with n-3 LC-PUFA. Adult male mice were fed a high-fat diet (cHF) for 8 weeks, or randomly assigned to various dietary treatments (i) cHF+F, cHF with n-3 LC-PUFA concentrate replacing 15% of dietary lipids; (ii) cHF+ROSI, cHF with rosiglitazone; (iii) cHF+F+ROSI; (iv) cHF+PIO, cHF with pioglitazone; and (v) cHF+F+PIO, or chow-fed. Plasma concentrations of 163 metabolites, development obesity, glucose homeostasis, plasma lipid levels and gene expression were evaluated. Both TZDs preserved glucose homeostasis and normal plasma lipid levels while inducing adiponectin. The beneficial effects of TZDs were further augmented by the combination treatments. Our results reveal differential effects of rosiglitazone and pioglitazone and support the notion that n-3 LC-PUFA could be used as add-on treatment to TZDs in order to improve diabetic patient’s therapy
Pracoviště	Fyziologický ústav
Kontakt	Lucie Trajhanová, lucie.trajhanova@fgu.cas.cz, Tel.: 241 062 400
Rok sběru	2012

Počet záznamů: 1